AMANDA MIXON: Open Payments
NPI 1174795017 · LONGMONT, CO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,174 in 18 payments from 9 companies in 2025. Trend: 2023 $91,740 · 2024 $30,052 · 2025 $1,174
Food & beverage: $1,174
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 6 | $450 |
| UCB, Inc. | 4 | $264 |
| AstraZeneca Pharmaceuticals LP | 2 | $141 |
| Amgen Inc. | 1 | $76 |
| GlaxoSmithKline, LLC. | 1 | $63 |
| E.R. Squibb & Sons, L.L.C. | 1 | $56 |
| Janssen Biotech, Inc. | 1 | $54 |
| Lilly USA, LLC | 1 | $41 |
| Boston Scientific Corporation | 1 | $29 |
Products named: KEVZARA, Bimzelx, TAVNEOS, BENLYSTA, TREMFYA, TALTZ, WaveWriter Alpha Prime 16, SAPHNELO.
Industry payments across CO — which companies pay providers there.
